Fact sheet: BB Biotech

Fund information

Fund name
BB Biotech B USD
Fund company manager
Bellevue Asset Management
Fund type
SIB
Fund manager(s)
Felicia Flanigan
since 31/08/2011
Dr.Tazio Storni
since 31/08/2011
Dallas Webb
since 31/08/2011
Lydia Bänziger
since 02/01/2012
Dr.. Daniel Koller
since 31/03/2009
Fund objective
The Fund’s investment objective is to generate attractive and competitive capital growth in the long term. It is therefore particularly suited to investors with an investment horizon of at least 5 years who want to selectively diversify their portfolio with investments in the biotechnology sector and who are willing to accept the equity risks typical of this sector.
Benchmark
Nasdaq Biotech Index
Investment style
Active,Growth
Investment method
Shares

Quick stats

1 Year return

19.31 %

1 Year rank in sector

10/30

Sector

FO Equity - Pharma Health & Biotech

Yield
-
Fund size

£ 56.3 m

FE Risk score

234

NAV
-
Discount/Premium
-
Gearing
-

Top in sector

Holdings snapshot

  • USA
    96.8%
  • Others
    2.1%
  • Money Market
    1.1%
  • Health Care
    56.8%
  • Pharmaceuticals
    17%
  • Healthcare & Medical Products
    15.2%
  • Others
    5.2%
  • Biotechnology/Medical
    4.7%
  • US Equities
    96.8%
  • Others
    2.1%
  • Money Market
    1.1%

Performance vs. Sector

Cumulative performance

1m6m1y3y5y
Fund5.06 %5.69 %20.19 %1.67 %116.72 %
Sector4.07 %3.17 %14.38 %11.78 %97.73 %
Rank within sector11 / 3110 / 3110 / 3022 / 267 / 22
Quartile th2 nd2 nd2 nd4 th2 nd

Calendar performance

YTD-20182017201620152014
Fund5.28 %23.13 %-24.69 %7.63 %36.33 %
Sector3.52 %14.94 %-9.92 %7.24 %28.08 %
Rank within sector3 / 317 / 3030 / 3013 / 266 / 23
Quartile th1 st1 st4 th2 nd2 nd

Risk statistics

Alpha-3.93
Beta1.61
Sharpe-0.01
Volatility26.28
Tracking error13.84
Information ratio-0.25
R-Squared0.86

Price movement

52 week high483.06
52 week low384.85
Current bid price0
Current offer price0
Current mid price478.58

Holdings by region

  • 96.8% USA
  • 2.1% Others
  • 1.1% Money Market

Holdings by sector

  • 56.8% Health Care
  • 17% Pharmaceuticals
  • 15.2% Healthcare & Medical Products
  • 5.2% Others
  • 4.7% Biotechnology/Medical
  • 1.1% Money Market

Holdings by asset type

  • 96.8% US Equities
  • 2.1% Others
  • 1.1% Money Market

Individual holdings

  • 8.4% BIOGEN INC
  • 8% GILEAD SCIENCES INC
  • 7.1% AMGEN INC
  • 6.3% CELGENE CORP
  • 5.9% REGENERON PHARMACEUTICALS INC
  • 4.7% ILLUMINA INC
  • 4.3% VERTEX PHARMACEUTICAL
  • 3.8% ALEXION PHARMACEUTICALS INC
  • 3.8% INCYTE CORP
  • 3.3% MYLAN NV